BMS part­ners with Grit­stone on sol­id tu­mor com­bos; Roche's Alzheimer's di­ag­nos­tic gets break­through sta­tus

→ Bris­tol-My­ers Squibb $BMY is team­ing up with Emeryville, CA-based Grit­stone On­col­o­gy to try out a can­cer com­bo against sol­id tu­mors. The com­pa­nies are try­ing BMS’ Op­di­vo and Yer­voy with Grit­sone’s per­son­al­ized neoanti­gen treat­ment. They’re start­ing out test­ing the Op­di­vo com­bo in com­mon sol­id tu­mors like metasta­t­ic non-small cell lung can­cer, gas­troe­sophageal, blad­der, and col­orec­tal can­cers. They’ll al­so test Grit­stone’s drug with sys­temic Op­di­vo and a lo­cal­ized in­jec­tion of Yer­voy. Grit­sone’s pres­i­dent and CEO An­drew Allen said this in a state­ment: “The emer­gence of im­munother­a­pies in the last decade has trans­formed the way we think about treat­ing can­cer, yet there re­mains a need for new ther­a­pies, which can ini­ti­ate im­mune sys­tem recog­ni­tion of tu­mors. We have de­vel­oped our pro­grams us­ing in­sights from our pro­pri­etary tu­mor anti­gen dis­cov­ery plat­form, EDGE, to­geth­er with an im­munother­a­py plat­form which has demon­strat­ed the abil­i­ty to elic­it an en­hanced anti­gen-di­rect­ed T-cell re­sponse in pre­clin­i­cal pri­mate mod­els.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.